Double maintains 3 strategies that include CLDX - Celldex Therapeutics, Inc.
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AEM | -0.06% | $60.01B | +74.43% | 1.35% |
| DUK | -0.07% | $90.99B | +17.25% | 3.56% |
| SO | 0.20% | $100.18B | +17.28% | 3.18% |
| CORT | -0.21% | $7.57B | +133.90% | 0.00% |
| EQX | -0.24% | $4.42B | +6.96% | 0.00% |
| DFDV | -0.26% | $300.56M | +2,130.16% | 0.00% |
| AGRO | 0.30% | $919.94M | -6.79% | 3.77% |
| PULM | 0.30% | $25.57M | +219.63% | 0.00% |
| CL | 0.31% | $74.88B | -3.64% | 2.19% |
| VSTA | -0.32% | $344.07M | +39.29% | 0.00% |
| UUU | -0.34% | $7.17M | +101.30% | 0.00% |
| KR | 0.34% | $46.43B | +38.38% | 1.85% |
| WBA | 0.43% | $9.95B | +3.51% | 4.36% |
| SATS | -0.45% | $8.47B | +60.36% | 0.00% |
| CCEC | -0.45% | $1.02B | +3.91% | 2.58% |
| CEF | 0.62% | - | - | 0.00% |
| PSQH | -0.64% | $98.82M | -36.55% | 0.00% |
| RLMD | 0.64% | $19.95M | -80.03% | 0.00% |
| MO | 0.66% | $99.67B | +28.77% | 6.90% |
| SOL | 0.78% | $96.48M | +16.05% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 64.70% | $4.82B | 0.35% |
| GNOM | 59.21% | $44.57M | 0.5% |
| IBB | 58.67% | $5.26B | 0.45% |
| PBE | 54.70% | $223.19M | 0.58% |
| ARKG | 53.50% | $1.02B | 0.75% |
| BBH | 52.27% | $330.62M | 0.35% |
| IWC | 51.16% | $818.14M | 0.6% |
| PINK | 50.27% | $130.57M | 0.5% |
| FBT | 49.86% | $1.01B | 0.54% |
| XPH | 49.37% | $147.96M | 0.35% |
| PTH | 49.09% | $100.85M | 0.6% |
| VTWO | 48.41% | $12.52B | 0.07% |
| IWM | 48.38% | $63.72B | 0.19% |
| IWO | 48.04% | $11.60B | 0.24% |
| KJUL | 47.79% | $119.50M | 0.79% |
| IWN | 47.09% | $10.96B | 0.24% |
| KJAN | 46.59% | $287.30M | 0.79% |
| SCHA | 46.52% | $17.26B | 0.04% |
| FYX | 46.32% | $817.02M | 0.6% |
| GSSC | 46.18% | $561.54M | 0.2% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| LTPZ | -0.07% | $674.52M | 0.2% |
| LMBS | 0.10% | $5.11B | 0.64% |
| CGSD | -0.15% | $1.32B | 0.25% |
| AGG | -0.16% | $129.47B | 0.03% |
| SPIP | 0.22% | $969.51M | 0.12% |
| PWZ | -0.28% | $759.91M | 0.28% |
| SCHZ | -0.28% | $8.59B | 0.03% |
| SCMB | 0.30% | $2.06B | 0.03% |
| TLTW | 0.31% | $1.15B | 0.35% |
| MTBA | -0.39% | $1.37B | 0.17% |
| UDN | 0.43% | $148.33M | 0.78% |
| EAGG | -0.45% | $3.99B | 0.1% |
| TAXF | -0.47% | $489.34M | 0.29% |
| FXE | 0.50% | $568.94M | 0.4% |
| FMF | -0.55% | $158.70M | 0.95% |
| SPAB | 0.57% | $8.82B | 0.03% |
| BIL | -0.59% | $42.24B | 0.1356% |
| EUSB | -0.64% | $735.36M | 0.12% |
| USDU | -0.65% | $162.43M | 0.5% |
| GNMA | -0.67% | $368.65M | 0.1% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| TAIL | -33.50% | $99.63M | 0.59% |
| VIXY | -32.20% | $164.54M | 0.85% |
| BTAL | -30.32% | $296.22M | 1.43% |
| CLIP | -12.82% | $1.51B | 0.07% |
| CTA | -12.74% | $1.06B | 0.76% |
| CGSM | -12.57% | $709.45M | 0.25% |
| ULST | -12.29% | $654.75M | 0.2% |
| PSQA | -11.91% | $35.44M | 0.2% |
| IVOL | -11.07% | $347.03M | 1.02% |
| DFNM | -10.96% | $1.57B | 0.17% |
| BSMW | -10.67% | $107.45M | 0.18% |
| TBLL | -10.40% | $2.13B | 0.08% |
| SHYM | -10.25% | $357.13M | 0.35% |
| MMIN | -9.95% | $336.10M | 0.3% |
| AGZ | -9.81% | $614.58M | 0.2% |
| MLN | -9.67% | $541.74M | 0.24% |
| FTSD | -9.57% | $231.81M | 0.25% |
| XONE | -9.52% | $625.28M | 0.03% |
| SPTS | -9.13% | $5.80B | 0.03% |
| FMHI | -8.80% | $754.85M | 0.7% |
Finnhub
Celldex Therapeutics, Inc. dropped from Russell 2500 Growth Index...
Finnhub
Celldex Therapeutics, Inc. dropped from Russell 3000 Growth Index...
Finnhub
Celldex Therapeutics, Inc. dropped from Russell Small Cap Comp Growth Index...
Finnhub
Celldex Therapeutics, Inc. dropped from Russell 2000 Growth Index...
Finnhub
HAMPTON - Celldex Therapeutics, Inc. announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company's Phase 2 clinical trial in chronic spontaneous...
Yahoo
77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52Data further support barzolvolimab clinical benefit to patients with CSU HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of t
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BEAM | 55.75% | $2.00B | -15.33% | 0.00% |
| DNLI | 55.34% | $2.16B | -30.05% | 0.00% |
| RVMD | 50.05% | $6.93B | +0.73% | 0.00% |
| CRNX | 49.77% | $2.76B | -33.39% | 0.00% |
| ATXS | 49.30% | $323.37M | -36.33% | 0.00% |
| APGE | 49.11% | $2.64B | +18.19% | 0.00% |
| IMVT | 48.81% | $2.87B | -35.84% | 0.00% |
| COGT | 48.76% | $843.67M | -11.36% | 0.00% |
| CGON | 48.46% | $2.03B | -13.46% | 0.00% |
| KRYS | 48.30% | $4.08B | -20.39% | 0.00% |
| OCUL | 48.12% | $1.51B | +41.41% | 0.00% |
| NRIX | 48.03% | $948.37M | -35.91% | 0.00% |
| RNA | 47.76% | $3.54B | -21.10% | 0.00% |
| IDYA | 46.92% | $1.92B | -34.15% | 0.00% |
| XENE | 46.58% | $2.56B | -7.61% | 0.00% |
| BLFS | 46.44% | $1.08B | +13.58% | 0.00% |
| CELC | 46.06% | $493.78M | -20.05% | 0.00% |
| ARCT | 45.80% | $369.38M | -37.89% | 0.00% |
| XNCR | 45.61% | $590.72M | -55.40% | 0.00% |
| ARWR | 45.41% | $2.33B | -32.59% | 0.00% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CBOE | -18.18% | $24.23B | +35.36% | 1.09% |
| K | -10.98% | $27.76B | +41.17% | 2.85% |
| GFI | -9.30% | $21.56B | +57.55% | 2.31% |
| LITB | -8.28% | $21.24M | -78.57% | 0.00% |
| DRD | -8.23% | $1.18B | +51.33% | 2.03% |
| STG | -6.91% | $30.78M | -22.51% | 0.00% |
| ED | -6.12% | $36.00B | +12.64% | 3.34% |
| DG | -5.93% | $25.41B | -7.95% | 2.05% |
| CME | -5.67% | $99.39B | +40.68% | 3.86% |
| VSA | -5.56% | $8.67M | -19.04% | 0.00% |
| HMY | -4.85% | $8.87B | +52.35% | 1.21% |
| AEP | -4.84% | $55.16B | +17.93% | 3.54% |
| EW | -4.74% | $45.18B | -15.44% | 0.00% |
| MKTX | -4.40% | $8.22B | +9.03% | 1.38% |
| AWK | -4.11% | $27.36B | +9.65% | 2.21% |
| AQB | -4.10% | $2.96M | -53.35% | 0.00% |
| DOGZ | -3.77% | $121.58M | -48.38% | 0.00% |
| LFVN | -3.10% | $168.68M | +123.71% | 1.22% |
| WM | -3.05% | $89.89B | +6.28% | 1.41% |
| CNC | -2.55% | $16.81B | -49.40% | 0.00% |
Current Value
$22.331 Year Return
Current Value
$22.331 Year Return
